Cross-border deal in biosimilars


OaklinsDealFlash_CrossBorderDealInBiosimilars_Healthcare_Nov2015 picOaklins’ Swedish and Italian teams advised the shareholders of Xbrane Biosciences AB (Xbrane) on the acquisition of Primm Pharma.

They supported the buyer by scouting the Italian market, identifying the most suitable target, and assisting in the LOI formulation and in negotiations throughout the process. Through the acquisition, Xbrane will be able to broaden their expertise within the field of high demand complex generics.

Read more about the transaction, market trends, deal drivers and M&A valuation aspects in the attached newsletter.